Given that the inhibitors for Na+/K+-ATPase show antitumor effects and the intimate connection between FXYD2 and Na+/K+-ATPase, there is great potential to explore targeted drugs again FXYD2 to assist in the treatment of ccRCC. Here, FXYD2 is linked to nonpapillary renal cell carcinoma.